$RGLS
Regulus Therapeutics Inc.

2014 Q1 Form 10-Q Financial Statement

#000119312514190461 Filed on May 09, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q1
Revenue $1.631M $3.238M
YoY Change -49.63% -3.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.730M $1.910M
YoY Change 42.93% 107.61%
% of Gross Profit
Research & Development $9.604M $6.883M
YoY Change 39.53% 49.53%
% of Gross Profit
Depreciation & Amortization $354.0K $289.0K
YoY Change 22.49% 28.44%
% of Gross Profit
Operating Expenses $12.34M $8.788M
YoY Change 40.37% 59.06%
Operating Profit -$10.71M -$5.550M
YoY Change 92.88% 154.59%
Interest Expense $11.00K $70.00K
YoY Change -84.29% -24.73%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.74M -$7.239M
YoY Change 75.99% 222.31%
Income Tax $1.000K -$10.00K
% Of Pretax Income
Net Earnings -$12.74M -$7.229M
YoY Change 76.25% 221.57%
Net Earnings / Revenue -781.18% -223.26%
Basic Earnings Per Share -$0.30 -$0.20
Diluted Earnings Per Share -$0.30 -$0.20
COMMON SHARES
Basic Shares Outstanding 43.17M shares 35.88M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.6M $90.70M
YoY Change 26.35%
Cash & Equivalents $8.476M $17.82M
Short-Term Investments $106.1M $72.90M
Other Short-Term Assets $3.500M $1.100M
YoY Change 218.18%
Inventory
Prepaid Expenses
Receivables $100.0K
Other Receivables $0.00
Total Short-Term Assets $118.2M $91.77M
YoY Change 28.83%
LONG-TERM ASSETS
Property, Plant & Equipment $3.805M $3.892M
YoY Change -2.24%
Goodwill
YoY Change
Intangibles $1.095M $1.176M
YoY Change -6.89%
Long-Term Investments
YoY Change
Other Assets $978.0K $190.0K
YoY Change 414.74%
Total Long-Term Assets $5.878M $5.258M
YoY Change 11.79%
TOTAL ASSETS
Total Short-Term Assets $118.2M $91.77M
Total Long-Term Assets $5.878M $5.258M
Total Assets $124.1M $97.03M
YoY Change 27.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.691M $398.0K
YoY Change 576.13%
Accrued Expenses $3.279M $2.335M
YoY Change 40.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.568M $12.69M
YoY Change -24.62%
LONG-TERM LIABILITIES
Long-Term Debt $13.40M $11.90M
YoY Change 12.61%
Other Long-Term Liabilities $1.361M $804.0K
YoY Change 69.28%
Total Long-Term Liabilities $1.361M $804.0K
YoY Change 69.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.568M $12.69M
Total Long-Term Liabilities $1.361M $804.0K
Total Liabilities $31.82M $41.16M
YoY Change -22.69%
SHAREHOLDERS EQUITY
Retained Earnings -$91.83M -$67.65M
YoY Change 35.74%
Common Stock $43.00K $36.00K
YoY Change 19.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $92.29M $55.87M
YoY Change
Total Liabilities & Shareholders Equity $124.1M $97.03M
YoY Change 27.91%

Cashflow Statement

Concept 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$12.74M -$7.229M
YoY Change 76.25% 221.57%
Depreciation, Depletion And Amortization $354.0K $289.0K
YoY Change 22.49% 28.44%
Cash From Operating Activities -$9.029M -$7.155M
YoY Change 26.19% 39.53%
INVESTING ACTIVITIES
Capital Expenditures $75.00K $77.00K
YoY Change -2.6% -78.25%
Acquisitions
YoY Change
Other Investing Activities -$10.41M -$15.67M
YoY Change -33.57% -341.82%
Cash From Investing Activities -$10.48M -$15.75M
YoY Change -33.43% -357.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.728M $85.00K
YoY Change 11344.71% 157.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.18M 173.0K
YoY Change 5784.97% -333.78%
NET CHANGE
Cash From Operating Activities -9.029M -7.155M
Cash From Investing Activities -10.48M -15.75M
Cash From Financing Activities 10.18M 173.0K
Net Change In Cash -9.331M -22.73M
YoY Change -58.95% -2567.97%
FREE CASH FLOW
Cash From Operating Activities -$9.029M -$7.155M
Capital Expenditures $75.00K $77.00K
Free Cash Flow -$9.104M -$7.232M
YoY Change 25.88% 31.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43356822 shares
CY2013Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
113368000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17822000
CY2014Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43346014 shares
CY2014Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10028609 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.15
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1459000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91828000
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2739000
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3279000
CY2014Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
5400000
CY2014Q1 us-gaap Liabilities
Liabilities
31820000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
43000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5816000 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43346014 shares
CY2014Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7488000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9568000
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-59000
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
859000
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
184131000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2691000
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1361000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
92287000
CY2014Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
13403000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124107000
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
978000
CY2014Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
140000
CY2014Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1095000
CY2014Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
113461000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3805000
CY2014Q1 us-gaap Assets
Assets
124107000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8476000
CY2014Q1 us-gaap Short Term Investments
ShortTermInvestments
106121000
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3492000
CY2014Q1 us-gaap Assets Current
AssetsCurrent
118229000
CY2014Q1 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
106147000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40552000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41787326 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.69
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5598000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41787326 shares
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6500000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10370000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1297000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
172518000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1172000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
93457000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79087000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4888000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3013000
CY2013Q4 us-gaap Liabilities
Liabilities
29608000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
42000
CY2013Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
11279000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123065000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
987000
CY2013Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
79000
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1128000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3768000
CY2013Q4 us-gaap Assets
Assets
123065000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17807000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
96198000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3098000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
117182000
CY2013Q4 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
96181000
CY2012Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2015-10-09
CY2013 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
42000
CY2013 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
25000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35872606 shares
CY2013Q1 us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.66 pure
CY2013Q1 us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.074 pure
CY2013Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.00325 pure
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7155000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3483910 shares
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
77000
CY2013Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-1761000
CY2013Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
CY2013Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
18074000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7239000
CY2013Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
294000
CY2013Q1 us-gaap Revenues
Revenues
3238000
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
225000
CY2013Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
28000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7214000
CY2013Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
1000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5550000
CY2013Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
27000
CY2013Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
72000
CY2013Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-7229000
CY2013Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-324000
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10000
CY2013Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
66000
CY2013Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-588000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1905000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
173000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
787000
CY2013Q1 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
15000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22730000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
8788000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3238000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
822000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
86000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
85000
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
116000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
289000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
787000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15748000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6883000
CY2013Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
2430000
CY2013Q1 rgls Tenant Improvement Allowance
TenantImprovementAllowance
482000
CY2014Q1 dei Trading Symbol
TradingSymbol
RGLS
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001505512
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
500000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.44
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42690200 shares
CY2014Q1 us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
0.65 pure
CY2014Q1 us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.074 pure
CY2014Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0026 pure
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9029000
CY2014Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1256232 shares
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
235000 shares
CY2014Q1 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
58000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.72
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3775379 shares
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</p> </div>
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.07
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
47000 shares
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
75000
CY2014Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-2124000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-43000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
CY2014Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
39780000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12740000
CY2014Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
301000
CY2014Q1 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
32000
CY2014Q1 us-gaap Interest Paid
InterestPaid
11000
CY2014Q1 us-gaap Revenues
Revenues
1631000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
385000
CY2014Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
34000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12784000
CY2014Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
1000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10705000
CY2014Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
61000
CY2014Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
100000
CY2014Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-18000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-12741000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-443000
CY2014Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-61000
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-438000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2732000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10181000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1400000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9331000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9728000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
487000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
354000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1400000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
12336000
CY2014Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5000000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1161000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-39000
CY2014Q1 us-gaap Interest Expense
InterestExpense
11000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1519000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10483000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9604000
CY2014Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
29372000

Files In Submission

Name View Source Status
0001193125-14-190461-index-headers.html Edgar Link pending
0001193125-14-190461-index.html Edgar Link pending
0001193125-14-190461.txt Edgar Link pending
0001193125-14-190461-xbrl.zip Edgar Link pending
d690364d10q.htm Edgar Link pending
d690364dex101.htm Edgar Link pending
d690364dex311.htm Edgar Link pending
d690364dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20140331.xml Edgar Link completed
rgls-20140331.xsd Edgar Link pending
rgls-20140331_cal.xml Edgar Link unprocessable
rgls-20140331_def.xml Edgar Link unprocessable
rgls-20140331_lab.xml Edgar Link unprocessable
rgls-20140331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending